600276 恒瑞医药
已收盘 06-05 15:00:00
资讯
新帖
简况
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
智通财经 · 06-05 09:55
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
智通财经 · 06-04
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
美团、京东、阿里、腾讯，集体下跌
第一财经 · 06-03
美团、京东、阿里、腾讯，集体下跌
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
智通财经 · 06-02
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
恒瑞医药累计回购1206万股 金额7.72亿元
财中社 · 06-02
恒瑞医药累计回购1206万股 金额7.72亿元
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
证券日报 · 06-01
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
证券日报 · 05-29
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
证券日报 · 05-29
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
证券日报 · 05-29
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
恒瑞医药：2025年全年公司实现营业收入316.29亿元，同比增长13.02%
证券日报网 · 05-29
恒瑞医药：2025年全年公司实现营业收入316.29亿元，同比增长13.02%
恒瑞医药鲁兹诺雷钠片获批；赛诺医疗递交H股上市申请｜医药早参
每日经济新闻 · 05-29
恒瑞医药鲁兹诺雷钠片获批；赛诺医疗递交H股上市申请｜医药早参
恒瑞医药(01276)：SHR4640片获得药品注册批准
智通财经 · 05-28
恒瑞医药(01276)：SHR4640片获得药品注册批准
恒瑞医药(600276.SH)：SHR-1819注射液获得药物临床试验批准通知书
智通财经 · 05-28
恒瑞医药(600276.SH)：SHR-1819注射液获得药物临床试验批准通知书
恒瑞医药宣布SHR4640获国家药监局批准用于治疗痛风及高尿酸血症患者
美股速递 · 05-28
恒瑞医药宣布SHR4640获国家药监局批准用于治疗痛风及高尿酸血症患者
低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红
新浪基金 · 05-27
低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红
恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书
智通财经 · 05-26
恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书
恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过
证券日报 · 05-25
恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过
恒瑞医药：2025年公司创新药销售收入163.42亿元
证券日报 · 05-22
恒瑞医药：2025年公司创新药销售收入163.42亿元
恒瑞医药：每股派0.2元，股权登记日为5月26日
南方财经网 · 05-20
恒瑞医药：每股派0.2元，股权登记日为5月26日
深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参
每日经济新闻 · 05-20
深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":47.08,"timestamp":1780642800000,"preClose":46.63,"halted":0,"volume":93026396,"delay":0,"changeRate":0.0097,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":0.45,"latestTime":"06-05 15:00:00","open":47.48,"high":48.72,"low":47,"amount":4447000000,"amplitude":0.0369,"askPrice":47.09,"askSize":123,"bidPrice":47.08,"bidSize":994,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":46.63,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":51.29,"lowLimit":41.97,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.91,"roa":"--","peRate":38.486062,"roe":"4.15%","epsLYR":1.19,"committee":0.413203,"marketValue":312479000000,"turnoverRate":0.0146,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.5,"timestamp":1780646952002,"preClose":53.35,"halted":0,"volume":5580278,"delay":0,"premium":"+0.19"},"floatMarketCap":300323000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2641619989","title":"港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641619989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641619989?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624500,"startTime":"0","endTime":"0","summary":"消息面上，据恒瑞医药官微消息，近日，在ASCO 2026年会上，公司创新药“双艾”组合联合经动脉化疗栓塞术对比单纯TACE治疗不可切除肝细胞癌的全国多中心、随机对照、III期研究亮相口头报告环节。该研究为这一“TACE联合靶免”治疗策略在uHCC中的应用提供了有力的循证支持。基于该研究，“双艾”组合联合TACE治疗不可切除的肝细胞癌的上市许可申请已于2026年年初获国家药监局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU2097828631.EUR","BK0060","BK4585","LU1255011170.USD","BK0239","01276","BK0028","LU1820825898.SGD","TACE","BK1191","LU2097828557.USD","BK0188","BK0012","BK4588","LU1969619763.USD","LU1023057109.AUD","LU1328615791.USD","LU1655091616.SGD","LU2543165471.USD","LU0405327148.USD","BK0196","LU2580892862.HKD","600276","LU1997244956.HKD","LU0405327494.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2289578879.USD","LU2097828805.USD","LU1781817850.SGD","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","LU2580892789.USD","LU0359201612.USD","LU1580142542.USD","LU1146622755.USD","VXUS","LU1997245177.USD","LU0359202008.SGD","LU1064130708.USD","LU0359201885.HKD","LU2148510915.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155910","title":"恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155910?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:18","pubTimestamp":1780564719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月4日，该公司斥资人民币1982.37万元回购42万股A股股份，每股回购价人民币46.7-47.7元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU2097828631.EUR","BK0060","LU1255011170.USD","BK0239","01276","399300","BK0028","LU1820825898.SGD","BK1191","LU2097828557.USD","BK0188","BK0012","LU1969619763.USD","LU1023057109.AUD","LU1328615791.USD","LU1655091616.SGD","LU2543165471.USD","LU0405327148.USD","BK0196","LU2580892862.HKD","600276","LU1997244956.HKD","LU0405327494.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2289578879.USD","LU2097828805.USD","LU1781817850.SGD","159982","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","LU2580892789.USD","LU0359201612.USD","LU1580142542.USD","LU1146622755.USD","LU1997245177.USD","LU0359202008.SGD","LU1064130708.USD","LU0359201885.HKD","LU2148510915.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640977122","title":"美团、京东、阿里、腾讯，集体下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640977122","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640977122?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:32","pubTimestamp":1780475520,"startTime":"0","endTime":"0","summary":"6月3日，香港恒生指数收跌1.56%，恒生科技指数跌2.74%。\n\n 科网股普跌，金蝶国际跌超7%，美团跌近6%，京东集团跌超4%，腾讯控股、阿里巴巴跌超3%。\n\n 生物医药板块下挫，药明生物、药明合联、恒瑞医药均大跌7%。\n编辑丨瑜见\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：孙同怀","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999006514.SGD","LU0348827113.USD","LU0633140560.USD","SGXZ81514606.USD","LU0175139822.USD","LU2362540622.SGD","07300","BK4538","LU1770034418.SGD","LU1226287792.SGD","LU0211977185.USD","LU0918141887.USD","LU0823040885.USD","LU0307460666.USD","LU1831875114.USD","LU1235295612.USD","LU1481107354.HKD","LU0577902454.USD","SG9999006597.SGD","BABW","BK4122","LU0949170772.SGD","LU2125910849.SGD","LU0593848301.USD","LU0886674414.USD","SG9999001903.USD","LU0650527681.SGD","03032","LU0143863784.USD","LU0345769128.USD","LU0269904917.USD","LU1734074674.USD","SG9999001226.SGD","LU0210526637.USD","02269","BK1233","00700","LU1439102457.SGD","LU0862451837.USD","BK1521","LU0516423174.USD","LU1655091616.SGD","BBYY","BK1609","LU0828237510.HKD","LU0173614495.USD","02800","LU1282648689.USD","LU0516423091.SGD","LU0823426308.USD","HK0000320264.USD","LU0128522744.USD","LU0823038988.USD","BK1608","LU0572939691.SGD","LU1003077747.HKD","LU0140636845.USD","LU0737861699.HKD","LU1810669033.SGD","LU0545039389.USD","SG9999013353.USD","03423","LU1188198961.HKD","07200","LU0164865239.USD","LU2488822045.USD","BK1588","BK4543","HHImain","IE00B0169L03.USD","LU3063872942.SGD","LU0127658192.USD","BK4526","LU0107464264.USD","LU2051468812.USD","LU1688375341.USD","LU1868837565.USD","LU1044876610.USD","LU0469268626.HKD","LU0106252389.USD","LU0868486357.SGD","IE00B5MMRT66.SGD","LU0516422366.SGD","LU0359201612.USD","LU1316542783.SGD","BABA","SG9999017495.SGD","LU1718418525.SGD","03088","HK0001040168.HKD","SG9999014674.SGD","LU1969619763.USD","BK4554","LU0327786744.USD","LU1675838814.USD","LU2087589342.USD","LU0210533765.USD","LU0577902298.EUR","LU0572940350.SGD","03690","LU0463099449.HKD","LU0819123356.HKD","LU2317271919.USD","LU0326950275.SGD","LU1044874839.SGD","LU1051769294.HKD","LU0588546209.SGD","LU0856984785.SGD","IE00B0JY6N72.USD","LU1282649810.SGD","LU0188438112.USD","BK4504","BK0188","LU2152927971.USD","LU0823039010.USD","LU0345769631.USD","LU1629966141.USD","LU0070217475.USD","LU0675040207.SGD","SG9999015945.SGD","LU0235996351.USD","IE00B031J352.USD","SG9999003461.SGD","IE00BGV7N243.SGD","BABU","LU0310800965.SGD","BK4548","83115","07226","LU0831103253.SGD","02837","BK4588","LU0588545904.SGD","LU0106959298.USD","LU0456846285.SGD","LU0642271901.SGD","LU0640798160.USD","LU0651946864.USD","LU0738912210.USD","LU0384037296.USD","LU1242518931.SGD","LU1814569148.SGD","LU1770036033.HKD","LU0348784397.USD","LU2449936058.SGD","LU0329678337.USD","LU0797268264.HKD","LU1196710351.USD","BK1619","LU0251143458.SGD","HK0000151867.HKD","LU1956131251.USD","LU2476274308.USD","LU0051755006.USD","LU1046421795.USD","IE0032834883.USD","03037","LU2279701549.SGD","LU0918141705.HKD","LU0054237671.USD","BK1141","LU1880383440.USD","LU0661504455.SGD","LU1951186391.HKD","LU2580892862.HKD","SG9999014906.USD","IE00B543WZ88.USD","IE0031814852.USD","IE00BQXX3D17.EUR","LU1366334651.USD","LU0192582467.USD","LU0049112450.USD","LU0540923850.HKD","LU0871576103.HKD","LU0605514214.HKD","LU1102505762.USD","LU0455707207.USD","LU0648948544.HKD","LU0315179316.USD","BK4585","LU0231483743.USD","LU1883866441.USD","LU0651947912.USD","IE00BQXX3F31.USD","LU0396098781.USD","BK4565","IE0009570106.USD","LU2148510915.USD","HK0000352382.USD","LU1568876251.USD","LU0328353924.USD","LU1719994722.HKD","LU0164880469.USD","LU0449509016.USD","LU0106259558.USD","LU1820825898.SGD","BK0239","HSI","LU0164872284.USD","IE0003895053.USD","BK1586","LU0737861772.HKD","LU2133065610.SGD","LU0672654166.SGD","LU0143863198.USD","LU1282649141.HKD","IE00BZ08YS42.EUR","LU1691799644.USD","IE0008369823.USD","SG9999000327.SGD","IE00BZ08YR35.GBP","IE0003851619.USD","LU0531970944.HKD","LU1568876335.HKD","SG9999002828.SGD","LU0029874905.USD","LU0128522157.USD","LU0449515922.USD","LU0577902538.SGD","LU2237443465.HKD","WXXWY","LU0165289439.USD","LU1725190679.HKD","LU0541501648.USD","LU0786609619.USD","07552","SG9999014914.USD","BK4581","LU1115378108.SGD","SG9999001846.SGD","LU0117844026.USD","SG9999014880.SGD","SGXZ31699556.SGD","LU0862451753.SGD","SGXZ51526630.SGD","LU0683595622.HKD","LU1046422090.SGD","BK4587","LU0979878070.USD","BK0196","LU0634319403.HKD","SG9999002562.SGD","LU0456827905.SGD","LU0499858438.USD","LU1048484197.HKD","LU1981816686.USD","LU1997245094.SGD","HK0000914660.USD","SG9999018865.SGD","LU1439103000.SGD","BK1604","LU1008478684.HKD","BK1610","LU0608807946.USD","IE00B031HW06.USD","LU1804176565.USD","LU0287142896.SGD","LU0348783662.USD","LU1580142542.USD","LU1504937902.USD","LU0898667661.SGD","LU1048596156.SGD","LU1282651121.HKD","LU0417516738.SGD","LU0985320562.USD","LU2097828805.USD","09988","BK0060","BK1589","LU2237443382.USD","LU0320764243.SGD","LU1993786604.SGD","LU1224709979.USD","LU0348816934.USD","LU0320764755.SGD","03419","BK4505","HK0000352291.HKD","IE00B8HQ1Z84.USD","LU0196878994.USD","LU0561508036.HKD","LU0738911758.USD","BK4220","LU0784639295.USD","LU0315178854.USD","LU1868837722.USD","LU2498475776.HKD","HK0000914686.HKD","LU0577902611.USD","LU0502904849.HKD","IE0003795394.USD","LU0607220059.USD","LU0345775950.USD","LU2023250504.SGD","LU2247934214.USD","LU0345776255.USD","LU0096374516.USD","LU1515016050.SGD","LU1974910355.USD","LU0553294199.USD","LU0084288322.USD","BK4575","IE00BFMHRM44.USD","KBAB","LU0417516902.SGD","LU1051768304.USD","LU0791591158.USD","LU0348783233.USD","LU0823397103.USD","LU1226288170.HKD","LU0289960550.SGD","LU0203347892.USD","LU0611395673.USD","LU2362541273.HKD","HMTD.SI","LU1769817179.HKD","09115","LU0264606111.USD","SG9999015978.USD","LU0259732245.USD","09067","SG9999001051.SGD","LU2265009873.SGD","BK4524","LU0067412154.USD","LU0819121731.USD","SG9999002463.SGD","LU0882747503.HKD","LU2495084118.USD","LU1211504680.USD","03115","BK4503","BK4502","LU2097828474.EUR","LU1997245177.USD","LU0633140727.USD","BK4614","IE00B031HY20.USD","LU0880133367.SGD","LU2289578879.USD","LU2399975544.HKD","LU0293314216.USD","LU0320764599.SGD","LU0169518387.USD","LU0488056044.USD","HK0000320223.HKD","LU0132412106.USD","BK1517","SG9999000459.SGD","IE0001KFT4U8.USD","BABX","BK4579","LU1242518857.USD","LU0828237940.HKD","LU0117841782.USD","BK1516","LU1064130708.USD","03033","LU0047713382.USD","BK4607","LU0348735423.USD","LU0054450605.USD","LU0865486749.SGD","BK4533","IE00B067MR52.USD","LU0405327494.USD","09618","LU0828238088.HKD","LU1282649067.USD","LU1781817850.SGD","LU0211331839.USD","LU0589944569.HKD","IE00B0169N27.USD","LU0163747925.USD","LU0203345920.USD","LU0405327148.USD","LU0251144936.SGD","LU2251237488.HKD","LU0072913022.USD","LU0878004406.USD","LU1023057109.AUD","LU0823397285.USD","HK0000306685.HKD","IE00BZ08YT58.USD","LU2177674079.SGD","IE0008368411.USD","LU2237443895.HKD","HTCD.SI","LU1880383366.USD","LU0359202008.SGD","LU0823426480.USD","LU2462611646.USD","BK1531","SGXZ99366536.SGD","IE00B97KM107.HKD","LU0594300179.USD","LU2237443622.USD","LU2778985437.USD","LU1997244956.HKD","LU1282651048.USD","BK4531","LU0878005551.USD","LU1235294995.USD","LU0543330566.HKD","LU1255011170.USD","LU0456842615.SGD","LU2293587155.HKD","MHImain","LU1226287875.USD","600276","IE00B3M56506.USD","LU0348723411.USD","LU0359201885.HKD","IE00BQXX3C00.GBP","SG9999015952.SGD","HK0001040143.USD","LU1044875133.USD","LU2125910500.SGD","LU0128525689.USD","LU0214875030.USD","LU1655091459.SGD","LU1794554557.SGD","LU2362541513.USD","LU1328615791.USD","LU0043850808.USD","BK1583","LU0700851271.USD","LU1226288097.SGD","LU0608807433.USD","LU0326948709.USD","03067","LU2039709279.SGD","LU2237443549.SGD","LU2476274720.SGD","LU0823413587.USD","MCHmain","LU2097828631.EUR","LU0516422440.USD","LU1769817096.USD","BK1502","LU0348825331.USD","LU0972618739.USD","SGXZ90724238.SGD","LU1366334578.USD","LU0414403682.SGD","LU0890818403.SGD","LU1807302812.USD","LU2148611432.USD","BK4558","LU0261947096.USD","513600","BK4527","LU0149721374.USD","LU2257852520.SGD","89618","LU0011963245.USD","LU1960683339.HKD","LU0048580855.USD","LU1917777945.USD","SG9999001093.SGD","SG9999004220.SGD","09088","LU0048597586.USD","BK1615","LU0348814723.USD","BK1576","LU1323998911.USD","BABO","LU1868838027.USD","82800","SG9999014898.SGD","LU2251237306.USD","LU0501845795.SGD","LU1267930227.SGD","LU0149534421.HKD","SG9999007991.SGD","LU0210527791.USD","LU0229945570.USD","LU0441854154.USD","LU0823413660.USD","LU0431992006.USD","LU1064131003.USD","IE0034224299.USD","LU1196710864.SGD","IE0032431581.USD","IE00BF5LJ272.USD","LU1642822792.SGD","LU1720050803.USD","LU0588545730.USD","LU1251922891.USD","LU1823568750.SGD","02833","BK1526","LU1808992512.USD","HSTECH","LU1813983027.USD","LU2008162690.USD","LU0314109678.HKD","LU2226246903.HKD","BK1249","IE0008368742.USD","BK4534","LU0181495838.USD","JD","LU0588545490.SGD","03417","SG9999018857.SGD","TCEHY","LU1226288253.USD","BK1575","LU0228367735.SGD","LU0417516571.SGD","IE00B8L5B284.USD","LU0039217434.USD","LU0052756011.USD","IE00B29SXG58.USD","LU1226287529.USD","LU0370786039.SGD","LU2242644610.SGD","LU0061477393.USD","LU0541502299.USD","LU0080751232.USD","LU1152091754.HKD","LU0531971595.HKD","LU0029875118.USD","BK4535","LU0708995153.HKD","BK1095","LU0254981946.USD","LU2097828557.USD","LU0048388663.USD","SG9999000418.SGD","LU0516422952.EUR","LU1328277881.USD","LU2328871848.SGD","LU1105468828.SGD","LU0348805143.USD","LU0509642566.USD","LU2097828714.EUR","LU1196710195.USD","LU0791590937.USD","01276","LU0072462343.USD","LU0594300419.USD","LU2294711473.HKD","SG9999001069.SGD","LU1303224171.USD","BK1591","LU0049853897.USD","SG9999001689.USD","HK0000306701.USD","LU2237443978.SGD","LU1152091168.USD","LU1733274390.USD","LU0348788117.USD","LU2580892789.USD","LU0873338254.USD","LU0228659784.USD","LU0823041008.USD","LU1224444064.USD","LU0052750758.USD","SG9999015986.USD","BK1142","LU1733274473.HKD","LU0499858602.USD","LU1048588211.SGD","LU0244354667.USD","BK0012","IE00BPRC5H50.USD","LU0543330483.HKD","LU1146622755.USD","LU0577902371.SGD","LU1785774172.SGD","LU0708995583.HKD","BK1618","BK0028","GB00BDT5M118.USD","MPNGY","LU0821914370.USD","BK0183","07500","LU2045819591.USD","LU0572944931.SGD","LU1102505929.USD","LU2106854487.HKD","LU0261950983.USD","LU1961090484.USD","LU0329678170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640491601","title":"恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640491601","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640491601?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:13","pubTimestamp":1780391596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，2026年5月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份0股。截至2026年5月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1,205.62万股，已回购股份占公司总股本的比例为0.18%，购买的最高价为人民币70.00元/股，最低价为人民币53.52元/股，已支付的总金额为人民币77,198.09万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1255011170.USD","LU2488822045.USD","BK0196","LU2580892789.USD","LU2289578879.USD","LU2543165471.USD","01276","LU1580142542.USD","LU0359202008.SGD","LU2097828631.EUR","LU1655091616.SGD","LU1146622755.USD","LU2580892862.HKD","BK0188","LU2097828805.USD","LU0405327494.USD","LU1969619763.USD","399300","BK0012","LU1997245177.USD","BK0183","LU1997244956.HKD","BK0060","LU1064130708.USD","LU2328871848.SGD","LU1781817850.SGD","LU2495084118.USD","LU0405327148.USD","LU0359201612.USD","LU1997245094.SGD","LU1328615791.USD","LU1023057109.AUD","600276","LU0359201885.HKD","LU2097828474.EUR","BK1191","LU1064131003.USD","LU2097828557.USD","LU1820825898.SGD","LU2148510915.USD","BK0239","LU2097828714.EUR","BK0028","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640167049","title":"恒瑞医药累计回购1206万股 金额7.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640167049","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640167049?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:07","pubTimestamp":1780391220,"startTime":"0","endTime":"0","summary":"6月2日，恒瑞医药（600276/01276）发布公告，截至2026年5月31日，公司已回购1206万股，占总股本的0.18%，累计回购金额为7.72亿元，回购价格区间为53.52元/股至70元/股。2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023757608896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","LU2580892789.USD","LU1146622755.USD","LU2097828631.EUR","LU1023057109.AUD","LU0359201885.HKD","LU1997245177.USD","LU0405327494.USD","BK0239","LU2097828714.EUR","LU2289578879.USD","01276","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","LU1255011170.USD","LU2097828805.USD","LU1997244956.HKD","LU1820825898.SGD","BK0183","LU1997245094.SGD","BK0196","BK0188","LU2328871848.SGD","LU2580892862.HKD","LU2097828557.USD","LU1064130708.USD","LU1781817850.SGD","LU1580142542.USD","BK0060","BK0028","LU0359201612.USD","LU1969619763.USD","LU2495084118.USD","LU1655091616.SGD","LU1328615791.USD","LU2097828474.EUR","LU0359202008.SGD","LU2543165471.USD","BK1191","LU0405327148.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640317951","title":"恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640317951","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640317951?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:01","pubTimestamp":1780315260,"startTime":"0","endTime":"0","summary":"证券日报网讯6月1日，恒瑞医药在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影响，公司日常经营管理和业务状况正常。公司坚持科技创新与国际化发展战略，致力于发展好主营业务，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756213975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","BK0188","LU2580892789.USD","BK0060","LU1997244956.HKD","LU2580892862.HKD","BK0183","LU2543165471.USD","LU1064130708.USD","LU1781817850.SGD","LU1820825898.SGD","BK0239","LU2148510915.USD","LU2097828714.EUR","BK0196","LU0405327148.USD","LU1328615791.USD","LU1580142542.USD","600276","01276","LU1255011170.USD","LU1146622755.USD","LU2097828631.EUR","LU2488822045.USD","LU2097828805.USD","LU2495084118.USD","LU1969619763.USD","LU0359201612.USD","BK1191","LU1064131003.USD","BK0028","LU1023057109.AUD","LU1997245177.USD","LU0359202008.SGD","LU2289578879.USD","LU2328871848.SGD","LU0359201885.HKD","LU1997245094.SGD","LU2097828474.EUR","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676739","title":"恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676739","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676739?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:59","pubTimestamp":1780066740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司将继续大力推进“科技创新”和“国际化”两大发展战略，稳步推进研发创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754793698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","BK0239","LU1255011170.USD","LU1328615791.USD","LU1655091616.SGD","LU2289578879.USD","LU0359201612.USD","BK0060","LU1064130708.USD","LU0359202008.SGD","LU0405327494.USD","LU1146622755.USD","BK0196","LU2495084118.USD","LU2543165471.USD","LU1580142542.USD","LU1997245094.SGD","LU1969619763.USD","LU2328871848.SGD","LU1997245177.USD","BK0183","LU2580892862.HKD","BK0012","LU0405327148.USD","LU2097828474.EUR","600276","LU2148510915.USD","01276","LU1064131003.USD","LU0359201885.HKD","LU2097828805.USD","LU2580892789.USD","LU1997244956.HKD","BK0028","LU1781817850.SGD","LU2097828714.EUR","BK0188","BK1191","LU2097828631.EUR","LU2488822045.USD","LU2097828557.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676731","title":"恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676731","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676731?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:58","pubTimestamp":1780066680,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，为保障2025年年度权益分派方案实施，公司本轮回购工作自权益分派实施筹备工作启动之日至权益分派实施完毕期间暂停。公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754790498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK0239","LU1580142542.USD","LU2148510915.USD","LU1328615791.USD","BK0183","LU1781817850.SGD","BK0012","LU1997245094.SGD","LU2580892789.USD","LU1023057109.AUD","LU1064130708.USD","BK0188","LU2097828805.USD","LU2289578879.USD","01276","LU0359201885.HKD","LU2543165471.USD","LU1146622755.USD","LU0359202008.SGD","LU1820825898.SGD","LU2097828714.EUR","BK0028","LU0405327148.USD","LU2495084118.USD","LU1255011170.USD","LU1969619763.USD","BK0196","LU2328871848.SGD","LU1064131003.USD","LU2580892862.HKD","BK1191","LU2097828557.USD","LU2097828631.EUR","LU0405327494.USD","LU1997244956.HKD","LU2488822045.USD","LU2097828474.EUR","LU0359201612.USD","600276","LU1655091616.SGD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676986","title":"恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676986","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676986?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:48","pubTimestamp":1780066080,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，目前已在中国获批上市25款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754780227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","LU1064130708.USD","LU2097828714.EUR","LU2580892789.USD","LU1064131003.USD","LU1580142542.USD","LU1255011170.USD","BK0028","LU2097828474.EUR","LU2097828631.EUR","LU0405327494.USD","BK0183","LU1997245094.SGD","600276","BK0012","159992","BK1191","LU1997244956.HKD","LU2148510915.USD","IPOS","LU2543165471.USD","LU0405327148.USD","LU2495084118.USD","LU0359201885.HKD","LU1146622755.USD","BK0188","BK1161","LU2580892862.HKD","LU2328871848.SGD","LU2097828557.USD","LU1781817850.SGD","LU2097828805.USD","LU2488822045.USD","BK0060","LU1023057109.AUD","LU2289578879.USD","BK1574","LU1655091616.SGD","LU0359201612.USD","LU1820825898.SGD","LU1997245177.USD","LU0359202008.SGD","LU1328615791.USD","LU1969619763.USD","BK0196","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639035620","title":"恒瑞医药：2025年全年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639035620","media":"证券日报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639035620?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:09","pubTimestamp":1780056540,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，二级市场波动受多重因素影响，公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。2026年第一季度，公司实现营业收入81.41亿元，同比增长12.98%；归属于上市公司股东的净利润22.82亿元，同比增长21.78%。公司始终高度重视全体股东利益，致力于发展好主营业务，促进公司业绩可持续增长，以更好的发展回馈股东。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-29/doc-inhzqptf9386509.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-29/doc-inhzqptf9386509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639142226","title":"恒瑞医药鲁兹诺雷钠片获批；赛诺医疗递交H股上市申请｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2639142226","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639142226?lang=zh_cn&edition=full","pubTime":"2026-05-29 07:00","pubTimestamp":1780009204,"startTime":"0","endTime":"0","summary":"｜2026年5月29日星期五｜NO.1石药集团+康宁杰瑞：安尼妥单抗注射液正式获批上市石药集团（HK01093）康宁杰瑞（HK09966）5月28日披露，双方联合研发的安尼妥单抗注射液获NMPA批准上市，适应证为联合化疗治疗既往经曲妥珠单抗治疗失败的HER2阳性晚期胃癌/胃食管结合部腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293753219246.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293753219246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","BK0239","LU1255011170.USD","LU1328615791.USD","09939","LU1655091616.SGD","LU2289578879.USD","LU0359201612.USD","BK0060","BK1515","LU0359202008.SGD","LU0405327494.USD","LU1064130708.USD","LU1146622755.USD","BK0196","LU2495084118.USD","LU2543165471.USD","LU1580142542.USD","LU1997245094.SGD","LU1969619763.USD","LU2328871848.SGD","LU1997245177.USD","BK1574","BK0183","LU2580892862.HKD","LU1023057109.AUD","BK0012","BK1161","LU0405327148.USD","LU2097828474.EUR","LU2148510915.USD","01276","BK0251","LU1064131003.USD","159938","LU0359201885.HKD","LU2097828805.USD","688108","LU2580892789.USD","IPOS","LU1997244956.HKD","BK0028","LU1781817850.SGD","LU2097828714.EUR","BK0188","BK1191","LU2097828631.EUR","LU2488822045.USD","LU2097828557.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638699141","title":"恒瑞医药(01276)：SHR4640片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2638699141","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638699141?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:51","pubTimestamp":1779976274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药鲁兹诺雷钠片上市，该产品是中国首个自主研发的新一代高选择性 URAT1 抑制剂。中国成人高尿酸血症患病率高达17.7%，约1.8亿人受其困扰;而痛风的患病率为3.2%，人数约 3600 万。全球范围内在售的痛风伴高尿酸血症的高选择性URAT1抑制剂仅有2020年1月获批的多替诺雷片，该产品已于2024年12月在中国获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1781817850.SGD","LU2328871848.SGD","LU2488822045.USD","LU0359201885.HKD","LU1064131003.USD","LU1064130708.USD","LU2097828557.USD","BK0196","BK0239","LU2543165471.USD","LU2097828631.EUR","BK0028","LU2148510915.USD","LU1580142542.USD","LU1328615791.USD","LU1255011170.USD","LU2580892789.USD","LU2580892862.HKD","600276","LU1997245177.USD","BK1191","LU1820825898.SGD","LU2097828805.USD","LU2097828714.EUR","LU1997244956.HKD","LU2097828474.EUR","BK0183","LU1997245094.SGD","BK0012","LU1969619763.USD","BK0188","LU1023057109.AUD","BK0060","LU0405327494.USD","01276","LU0359201612.USD","LU1146622755.USD","LU2289578879.USD","LU0405327148.USD","LU0359202008.SGD","LU2495084118.USD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667976","title":"恒瑞医药(600276.SH)：SHR-1819注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638667976?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:04","pubTimestamp":1779959083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于SHR-1819注射液的《药物临床试验批准通知书》，将于近期开展临床试验。申请的适应症：6月-5岁儿童特应性皮炎。SHR-1819注射液是公司自主研发的一种靶向人IL-4Rα的重组人源化单克隆抗体，能够同时阻断IL-4和IL-13的信号传导，在研适应症覆盖特应性皮炎、结节性痒疹、慢性自发性荨麻疹、过敏性鼻炎等多种2型炎症疾病，多项已进入Ⅱ/Ⅲ期临床阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU0359201885.HKD","LU0359201612.USD","LU0405327148.USD","BK0028","LU2097828805.USD","LU1328615791.USD","BK0183","LU0405327494.USD","LU1255011170.USD","LU2097828557.USD","BK0060","BK0196","LU1997245094.SGD","LU1820825898.SGD","LU2488822045.USD","LU2580892789.USD","LU1997245177.USD","LU2097828631.EUR","LU2495084118.USD","LU0359202008.SGD","BK0239","600276","BK0012","LU1969619763.USD","01276","LU2289578879.USD","BK0188","LU1781817850.SGD","LU1146622755.USD","LU1655091616.SGD","LU1064130708.USD","LU1580142542.USD","BK1191","LU1023057109.AUD","LU2328871848.SGD","LU1064131003.USD","LU2097828474.EUR","LU2543165471.USD","LU2097828714.EUR","LU2580892862.HKD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108182842","title":"恒瑞医药宣布SHR4640获国家药监局批准用于治疗痛风及高尿酸血症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1108182842","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108182842?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:01","pubTimestamp":1779958884,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其研发的创新药SHR4640已获得中国国家药品监督管理局的上市批准，适用于痛风及高尿酸血症患者的治疗。这一批准标志着该药物正式进入临床应用阶段，为相关疾病患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU2097828631.EUR","LU1064130708.USD","BK0196","LU2097828474.EUR","LU0405327494.USD","LU1969619763.USD","LU1997244956.HKD","LU0405327148.USD","LU2580892862.HKD","LU1781817850.SGD","LU1580142542.USD","BK0028","600276","LU2495084118.USD","BK0183","LU1255011170.USD","LU2488822045.USD","LU1064131003.USD","LU2289578879.USD","LU1655091616.SGD","LU1146622755.USD","LU2097828557.USD","LU2148510915.USD","LU1328615791.USD","BK0188","BK0060","LU2328871848.SGD","LU1997245177.USD","LU1820825898.SGD","LU2097828714.EUR","LU1997245094.SGD","LU2580892789.USD","BK0012","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638957196","title":"低位制药板块韧性凸显，华宝基金药ETF（562050）午后逆市拉升！权重股恒瑞医药冲高4%，中药龙头集体飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2638957196","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638957196?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:22","pubTimestamp":1779862920,"startTime":"0","endTime":"0","summary":"5月27日午后，A股突发跳水，沪指失守4100点。制药板块局部异动，权重龙头恒瑞医药快速拉升翻红，一度冲高超4%；中药股逆市表现，云南白药、以岭药业、东阿阿胶、片仔癀等集体飘红。 场内唯一表征制药板块整体行情的药ETF华宝午后自深水区直线拉升，截至发稿跌0.22%，沪指跌1.41%。 低位布局“创新药+中药”，认准场内唯一药ETF华宝及其场外联接基金，汇聚A股50大龙头药企，在重仓创新药的同时，有约25%的权重为中药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-27/doc-inhzikrs0846612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1328615791.USD","LU2580892862.HKD","LU1997245094.SGD","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU2328871848.SGD","BK0188","LU2097828714.EUR","BK1574","BK0183","LU1997244956.HKD","FDN","01276","562050","LU0359201612.USD","LU1997245177.USD","BK1191","LU2097828631.EUR","LU2488822045.USD","BK0239","LU1064131003.USD","LU2580892789.USD","LU1969619763.USD","BK0028","LU0405327148.USD","LU2097828557.USD","LU1580142542.USD","LU1781817850.SGD","BK4588","LU2097828805.USD","LU1064130708.USD","LU2289578879.USD","LU1255011170.USD","LU2495084118.USD","BK0196","600276","LU1655091616.SGD","BK0060","01477","LU1023057109.AUD","BK0012","LU1820825898.SGD","BK4585","LU2097828474.EUR","LU0405327494.USD","LU2148510915.USD","LU1146622755.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638592066","title":"恒瑞医药(600276.SH)：HRS-1635片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638592066","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638592066?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:49","pubTimestamp":1779785384,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1635片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1635片是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞恶性肿瘤。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1635片相关项目累计研发投入约2,360万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1997245177.USD","LU1655091616.SGD","LU2097828631.EUR","BK0196","LU2495084118.USD","BK0060","LU2097828557.USD","LU1064130708.USD","LU1328615791.USD","BK0188","LU2289578879.USD","BK1191","LU1820825898.SGD","LU2580892789.USD","LU2580892862.HKD","LU1023057109.AUD","LU2097828474.EUR","LU1997244956.HKD","LU2488822045.USD","LU2543165471.USD","LU0359201885.HKD","LU2097828805.USD","LU1255011170.USD","600276","LU1781817850.SGD","LU1064131003.USD","LU1580142542.USD","BK0183","LU2328871848.SGD","BK0239","BK0012","LU0405327494.USD","LU1146622755.USD","LU1997245094.SGD","LU2097828714.EUR","LU2148510915.USD","01276","LU1969619763.USD","LU0359202008.SGD","LU0405327148.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558983","title":"恒瑞医药：公司2025年度利润分配方案经公司2025年年度股东会审议通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558983","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638558983?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:21","pubTimestamp":1779711660,"startTime":"0","endTime":"0","summary":"证券日报网讯5月25日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年度利润分配方案经公司2025年年度股东会审议通过，将按既定方案进行，具体详见公司在交易所网站发布的公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748385364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU1328615791.USD","LU2289578879.USD","600276","LU2543165471.USD","LU1997244956.HKD","01276","LU2488822045.USD","LU1820825898.SGD","LU2328871848.SGD","BK0060","BK0183","BK0188","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","BK1191","LU2097828714.EUR","LU1969619763.USD","LU1255011170.USD","LU0359201612.USD","LU1023057109.AUD","LU1064130708.USD","BK0196","LU1997245094.SGD","LU2097828631.EUR","LU0405327148.USD","LU0359201885.HKD","BK0028","LU2495084118.USD","LU2148510915.USD","BK0239","LU2097828805.USD","LU1781817850.SGD","LU1997245177.USD","LU2097828474.EUR","BK0012","LU1580142542.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637126963","title":"恒瑞医药：2025年公司创新药销售收入163.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637126963","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637126963?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:59","pubTimestamp":1779454740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月22日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，已在中国获批上市24款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747010910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU1064131003.USD","LU0405327494.USD","LU1997244956.HKD","BK1574","LU2289578879.USD","06978","LU1781817850.SGD","159992","LU1820825898.SGD","LU1997245177.USD","LU2580892789.USD","01276","LU2097828631.EUR","BK0183","LU1328615791.USD","LU0359201885.HKD","LU1146622755.USD","LU2580892862.HKD","LU2097828714.EUR","BK1191","LU1969619763.USD","LU1997245094.SGD","LU1580142542.USD","BK0188","LU2495084118.USD","LU2328871848.SGD","LU0359201612.USD","LU0359202008.SGD","LU1255011170.USD","LU2097828557.USD","LU2543165471.USD","BK0196","LU1064130708.USD","LU2097828805.USD","BK0028","LU2097828474.EUR","BK0060","BK1161","LU2148510915.USD","600276","BK0239","LU2488822045.USD","BK0012","LU0405327148.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845172","title":"恒瑞医药：每股派0.2元，股权登记日为5月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845172","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845172?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:21","pubTimestamp":1779272460,"startTime":"0","endTime":"0","summary":"南财智讯5月20日电，恒瑞医药发布2025年年度权益分派实施公告，公司本次利润分配方案为每股派发现金红利0.2元（含税），共计派发现金红利12.74亿元。本次权益分派股权登记日为2026年5月26日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743627742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","BK0188","LU2580892789.USD","BK0060","LU1997244956.HKD","LU2580892862.HKD","BK0183","LU2543165471.USD","LU1064130708.USD","LU1781817850.SGD","LU1820825898.SGD","BK0239","LU2148510915.USD","LU2097828714.EUR","BK0196","LU0405327148.USD","LU1328615791.USD","LU1580142542.USD","600276","01276","LU1255011170.USD","LU1146622755.USD","LU2097828631.EUR","LU2488822045.USD","LU2097828805.USD","LU2495084118.USD","LU1969619763.USD","LU0359201612.USD","BK1191","LU1064131003.USD","BK0028","LU1023057109.AUD","LU1997245177.USD","LU0359202008.SGD","LU2289578879.USD","LU2328871848.SGD","LU0359201885.HKD","LU1997245094.SGD","LU2097828474.EUR","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636896784","title":"深耕肠外营养领域，恒瑞医药新产品获批强化管线矩阵｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2636896784","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636896784?lang=zh_cn&edition=full","pubTime":"2026-05-20 09:22","pubTimestamp":1779240142,"startTime":"0","endTime":"0","summary":"截至5月19日收盘，市场探底回升，沪指、深成指先后翻红。医药ETF（512120）收平，港股通生物科技ETF（159102）上涨0.27%。相关个股中，恒瑞医药下跌1.6%、药明合联上涨3.28%、科伦博泰生物上涨1.27%、万泰生物下跌1.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203742884813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203742884813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1997244956.HKD","LU2543165471.USD","BK0060","LU2097828805.USD","LU1820825898.SGD","BK0012","LU2097828474.EUR","LU2289578879.USD","BK1574","LU2488822045.USD","BK0028","01276","LU1580142542.USD","LU1655091616.SGD","LU2328871848.SGD","LU2580892862.HKD","LU1997245094.SGD","LU0359201612.USD","09939","600276","LU2097828557.USD","LU1997245177.USD","LU1969619763.USD","LU1023057109.AUD","LU2097828631.EUR","LU1064130708.USD","LU1781817850.SGD","BK1191","BK1161","159938","LU0359201885.HKD","LU1146622755.USD","LU1255011170.USD","LU0405327494.USD","BK0183","BK0239","LU2148510915.USD","LU0405327148.USD","LU1328615791.USD","BK1515","BK0188","LU2097828714.EUR","LU2580892789.USD","LU0359202008.SGD","LU1064131003.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780854575510,"stockEarnings":[{"period":"1week","weight":-0.062},{"period":"1month","weight":-0.1185},{"period":"3month","weight":-0.1492},{"period":"6month","weight":-0.2328},{"period":"1year","weight":-0.1226},{"period":"ytd","weight":-0.2064}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}